MedCity News December 3, 2021
AviadoBio’s gene therapies are designed to achieve widespread distribution throughout the central nervous system. The company’s lead program on track to begin human testing as a treatment for frontotemporal dementia.
A biotech company with an answer for one of the challenges facing gene therapies for neurodegenerative disorders is out of stealth with a former Novartis executive at the helm and $80 million to support its research.
The lead program of AviadoBio is a gene therapy for frontotemporal dementia. The London-based startup plans to use the Series A round of funding to advance that candidate into human testing, and to continue work on preclinical assets that include a potential gene therapy for amyotrophic lateral sclerosis.
AviadoBio’s technology is based on research...
Today's Sponsors
Today's Sponsor